PFE: Leadership change

Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial, operational, accounting or reporting policies or practices. In connection with Mr. Denton’s departure, the Company announced that Cecile Guegan, the Company’s Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer, effective August 16, 2026, while the Company conducts a comprehensive process to identify Mr. Denton’s successor. Ms. Guegan, 55, joined Pfizer in 2005 and has served in her current role since 2022. Previously, Ms. Guegan served in various leadership roles within Pfizer’s finance organization, including as Vice President, Finance, Research & Development and Business Office from 2020 to 2022. A copy of the Company’s press release announcing Mr. Denton’s departure and Ms. Guegan’s interim appointment is attached hereto as Exhibit 99.1 and is incorporated by reference herin. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release of Pfizer Inc. dated June 18, 2026 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on